Analyzing Oncobiologics (NASDAQ:OTLK) and Xenetic Biosciences (NASDAQ:XBIO)

Oncobiologics (NASDAQ:OTLK) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Oncobiologics and Xenetic Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Xenetic Biosciences	1	0	0	0	1.00

Oncobiologics currently has a consensus target price of $5.20, suggesting a potential upside of 954.77%. Given Oncobiologics’ stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than Xenetic Biosciences.

Volatility and Risk

Oncobiologics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Earnings & Valuation

This table compares Oncobiologics and Xenetic Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	88.90	-$62.42 million	($0.77)	-0.64
Xenetic Biosciences	$2.98 million	1.48	-$2.68 million	($1.16)	-1.66

Xenetic Biosciences has higher revenue and earnings than Oncobiologics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oncobiologics beats Xenetic Biosciences on 7 of the 13 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.